What is Innovent Biologics Earnings Yield (Joel Greenblatt) %?
Innovent Biologics's Enterprise Value for the quarter that ended in Dec. 2023 was $7,559.8 Mil.
Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-146.4 Mil. Innovent Biologics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -1.84%.
The historical rank and industry rank for Innovent Biologics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
IVBIY'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -288.4 Med: -4.52 Max: -0.74
Current: -1.93
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Innovent Biologics was -0.74%. The lowest was -288.40%. And the median was -4.52%.
IVBIY's Earnings Yield (Joel Greenblatt) % is ranked better than 75.93% of 1400
companies
in the Biotechnology industry
Industry Median: -14.76
vs IVBIY: -1.93
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Innovent Biologics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Innovent Biologics Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Innovent Biologics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's Earnings Yield (Joel Greenblatt) %
For the Biotechnology subindustry, Innovent Biologics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Innovent Biologicss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Innovent Biologics Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics (Innovent Biologics) Business Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IVBIY has been successfully added to your 